PDCL2 Inhibitors
PDCL2 inhibitors are a class of chemical compounds that target the PDCL2 protein, which stands for Phosducin-Like Protein 2. This protein is a member of the phosducin family and plays a role in various cellular processes by interacting with other proteins within the cell. The inhibition of PDCL2 by specific small molecules can influence the function of this protein, thereby affecting the associated cellular mechanisms. The design of PDCL2 inhibitors is a complex process that requires a deep understanding of the protein's structure, the nature of the binding site, and the interactions that the inhibitor must engage with to effectively prevent the protein from carrying out its normal function.
The molecular architecture of PDCL2 inhibitors is characterized by their ability to fit into the binding sites of the PDCL2 protein, thereby preventing the protein from interacting with its natural partners. High specificity and affinity are crucial for the efficacy of these inhibitors, as they must selectively bind to PDCL2 without affecting other proteins with similar structures or functions. The development of these inhibitors involves a detailed analysis of the PDCL2 protein's three-dimensional structure, often utilizing techniques such as X-ray crystallography or NMR spectroscopy. Through such analyses, researchers can identify key amino acid residues within the protein that are critical for the binding of the inhibitor. Subsequent chemical synthesis of inhibitors is then tailored to interact with these residues, often involving the incorporation of functional groups that can form hydrogen bonds, ionic interactions, or hydrophobic contacts with the target protein, stabilizing the inhibitor-PDCL2 complex and effectively modulating the protein's activity at a molecular level.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib targets the epidermal growth factor receptor (EGFR) tyrosine kinase, which can indirectly affect the chaperone activity of PDCL2. Inhibition of EGFR can reduce the stabilization of proteins that rely on chaperone functions, potentially diminishing PDCL2's role in assisting protein folding and stabilization. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $412.00 | 32 | |
Lapatinib is a dual tyrosine kinase inhibitor that impacts EGFR and HER2/neu receptors. By inhibiting these receptors, Lapatinib may interfere with signaling pathways that necessitate chaperone activities, thereby indirectly affecting PDCL2's function in protein maturation. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
Erlotinib selectively inhibits EGFR tyrosine kinase. The downstream effect of EGFR inhibition can alter the demand for chaperone-mediated protein processing, potentially reducing PDCL2's functional activity in the cell. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib is a kinase inhibitor that acts on multiple targets, including VEGFR, PDGFR, and RAF kinases. By modulating these pathways, Sorafenib could indirectly affect PDCL2 by altering the cellular environment that relies on the chaperone activity of PDCL2 for protein stability. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $150.00 $920.00 | 5 | |
Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor, affecting pathways such as VEGFR and PDGFR. The inhibition of these kinases could alter the protein folding environment, indirectly affecting PDCL2's role as a chaperone. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $112.00 $163.00 $928.00 | 19 | |
Trametinib is a MEK inhibitor that impacts the MAPK/ERK pathway. Altering this pathway can change the cellular needs for chaperone activity, potentially modulating PDCL2's interaction with client proteins. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is a proteasome inhibitor that can lead to an accumulation of misfolded proteins. This accumulation can stress chaperone systems, indirectly impacting PDCL2's ability to function efficiently. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
MG-132 is a proteasome inhibitor similar to Bortezomib, with the potential to disrupt normal chaperone activities by causing protein aggregation, which may affect PDCL2's chaperone function. | ||||||
17-AAG | 75747-14-7 | sc-200641 sc-200641A | 1 mg 5 mg | $66.00 $153.00 | 16 | |
17-AAG is an Hsp90 inhibitor that disrupts its chaperone function. Given that Hsp90 is part of the molecular chaperone complex, inhibition of Hsp90 could indirectly impair PDCL2's ability to assist in the folding of nascent polypeptides. | ||||||
Celastrol, Celastrus scandens | 34157-83-0 | sc-202534 | 10 mg | $155.00 | 6 | |
Celastrol is a triterpene that induces heat shock response and inhibits Hsp90. This can lead to a compensatory increase in other chaperones while potentially overloading the chaperone machinery, including PDCL2. | ||||||